ADAP Stock - Adaptimmune Therapeutics plc
Unlock GoAI Insights for ADAP
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $178.03M | $60.28M | $27.15M | $6.15M | $3.96M |
| Gross Profit | $177.96M | $50.42M | $-100,578,000 | $-104,941,000 | $-87,610,000 |
| Gross Margin | 100.0% | 83.6% | -370.5% | -1706.6% | -2213.5% |
| Operating Income | $-68,760,000 | $-138,038,000 | $-163,965,000 | $-162,246,000 | $-133,405,000 |
| Net Income | $-70,814,000 | $-113,871,000 | $-165,456,000 | $-158,090,000 | $-130,092,000 |
| Net Margin | -39.8% | -188.9% | -609.5% | -2571.0% | -3286.8% |
| EPS | $-0.28 | $-0.57 | $-1.02 | $-1.02 | $-0.90 |
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and neck cancer; and in phase I clinical trials for urothelial, melanoma, head and neck, ovarian, non-small cell lung, esophageal and gastric, synovial sarcoma, and MRCLS cancers. The company is also developing ADP-A2AFP, which is in phase I clinical trials for hepatocellular carcinoma; and ADP-A2M4CD8, which is in phase I clinical trial for SPEAR T-cells focusing on treating patients with lung, gastroesophageal, head and neck, ovarian, and bladder cancers. It has a collaboration and license agreement with GSK; third party collaborations with Noile-Immune Biotech Inc., Alpine Immune Sciences, Inc., and National Center for Cancer Immune Therapy in Denmark; strategic alliance agreement with the MD Anderson Cancer Center; and co-development and co-commercialization agreement with Universal Cells, Inc. Adaptimmune Therapeutics plc also has a strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic T-cell therapies utilizing aß T-cell receptors. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| July 29th 2025 | H.C. Wainwright | Downgrade | Neutral | - |
| June 26th 2025 | Mizuho | Downgrade | Neutral | $0.5 |
| July 30th 2024 | H.C. Wainwright | Initiation | Buy | $4 |
| May 30th 2024 | Scotiabank | Initiation | Sector Outperform | $3.15 |
| March 24th 2023 | Bryan Garnier | Initiation | Buy | $3.6 |
| January 3rd 2023 | Guggenheim | Upgrade | Buy | $5 |
| November 9th 2022 | Mizuho | Upgrade | Buy | $9 |
Earnings History & Surprises
ADAPEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q4 2025 | Nov 12, 2025 | $-0.09 | $-0.07 | +22.2% | ✓ BEAT |
Q3 2025 | Aug 13, 2025 | $-0.15 | $-0.11 | +26.7% | ✓ BEAT |
Q2 2025 | May 13, 2025 | $-0.18 | $-0.18 | 0.0% | = MET |
Q1 2025 | Mar 24, 2025 | $-0.17 | $-0.26 | -52.9% | ✗ MISS |
Q4 2024 | Nov 13, 2024 | $-0.17 | $-0.07 | +58.8% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.07 | $0.24 | +442.9% | ✓ BEAT |
Q2 2024 | May 15, 2024 | $-0.16 | $-0.18 | -12.5% | ✗ MISS |
Q1 2024 | Mar 6, 2024 | $-0.12 | $-0.24 | -100.0% | ✗ MISS |
Q4 2023 | Nov 8, 2023 | $-0.20 | $-0.20 | 0.0% | = MET |
Q3 2023 | Aug 9, 2023 | $-0.17 | $-0.21 | -23.5% | ✗ MISS |
Q2 2023 | May 12, 2023 | $-0.19 | $0.01 | +105.3% | ✓ BEAT |
Q1 2023 | Mar 6, 2023 | $-0.25 | $-0.18 | +28.0% | ✓ BEAT |
Q4 2022 | Nov 8, 2022 | $-0.28 | $-0.24 | +14.3% | ✓ BEAT |
Q3 2022 | Aug 4, 2022 | $-0.28 | $-0.28 | 0.0% | = MET |
Q2 2022 | May 9, 2022 | $-0.26 | $-0.32 | -23.1% | ✗ MISS |
Q1 2022 | Mar 14, 2022 | $-0.22 | $-0.25 | -13.6% | ✗ MISS |
Q4 2021 | Nov 4, 2021 | $-0.27 | $-0.27 | 0.0% | = MET |
Q3 2021 | Aug 9, 2021 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q2 2021 | May 6, 2021 | $-0.25 | $-0.24 | +4.0% | ✓ BEAT |
Q1 2021 | Feb 25, 2021 | $-0.23 | $-0.24 | -4.3% | ✗ MISS |
Latest News
Adaptimmune Therapeutics shares are trading lower after the company announced it will delist from the Nasdaq.
📉 NegativeTrading Halt: Halt status updated at 8:05:00 AM ET: Quotation Resumption: News and Resumption Times
➖ NeutralAdaptimmune Therapeutics Board Determines To Initiate Delisting Of ADSs, Each Representing Six Ordinary Shares, From Nasdaq
📉 NegativeTrading Halt: Halted at 7:40:35 a.m. ET - Trading Halt: Halt News Pending
➖ NeutralAdaptimmune Sales Jump 59 Percent
📈 PositiveFrequently Asked Questions about ADAP
What is ADAP's current stock price?
What is the analyst price target for ADAP?
What sector is Adaptimmune Therapeutics plc in?
What is ADAP's market cap?
Does ADAP pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to ADAP for comparison